

**This is a free translation into English of the executive board report issued in French and provided solely for the convenience of English speaking users.**

## LIST OF POSITIONS HELD BY THE EXECUTIVE DIRECTORS

### I- Executive Board

<b>First and last name, age <sup>(1)</sup></b>	<b>Duration of Term</b>	<b>Position</b>	<b>Other Positions and Appointments held in any other company over the last five years</b>
Hervé Brailly French age 53	First appointment: Supervisory Board meeting of Jun. 13, 2005 renewed by Supervisory Board meeting of Jun. 29, 2011 then by the Supervisory Board meeting of March 27, 2014. Term expires: General Meeting of shareholders held in 2017 to vote on the accounts for the fiscal year ending on Dec. 31, 2016	Chairman of the Executive Board - CEO	No position within a listed company. Member of the supervisory board of Inserm Transfert (not renewed in 2014); Member of the executive committee and treasury of EuroBioMed; Member of the development council of the "Marseille Provence Metropole"; Elected member of the Chamber of Commerce of Marseille (2007-2012); Member of the Strategy and Prospects Committee of Aix Marseille University; Member of the Investment Committee of SATT Sud Est. Within the Innate Pharma Group: Member of the Board of Innate Pharma, Inc.; Member of the Executive Board of Platine Pharma Services (not renewed in 2014).
Catherine Moukheibir Lebanese Age 55	First appointment: Supervisory Board meeting of May 5th, 2011, renewed by Supervisory Board meeting of Jun. 29, 2011, then by the Supervisory Board meeting of March 27, 2014. Term expires: General Meeting of shareholders held in 2017 to vote on the accounts for the fiscal year ending on Dec. 31, 2016	Member of the Executive Board – Consultant Senior Finance Advisor	<u>Position currently held in a listed company:</u> Member of Supervisory Board and Audit Committee of Ablynx (from June 2013). Chairman of the Audit Committee of Octoplus (listed company) (2012-2013). <u>Positions in unlisted companies:</u> Partner in the consultancy firm STJ Advisors (2011-2013); Member of Supervisory Board and Member of Audit Committee of Creabilis (from December 2012); observer in board of Zealand Pharma A/S
Nicolai Wagtmann Danish Age 51	First appointment: Supervisory Board meeting of December 12, 2013, replacing Mr François Romagné. Renewed by the Supervisory Board meeting of March 27, 2014. Term expires: General Meeting of shareholders held in 2017 to vote on the accounts for the fiscal year ending on Dec. 31, 2016	Member of the Executive Board Chief Scientific Officer	None

- (1) For the purposes of their appointment, the members of the Company's Executive Board are located at the Company's head office.
- (2) Catherine Moukheibir is linked to the Company by a consulting agreement (see **Erreur ! Source du renvoi introuvable.** of the reference document).

*This is a free translation into English of the executive board report issued in French and provided solely for the convenience of English speaking users.*

## **II- Supervisory Board**

***This is a free translation into English of the executive board report issued in French and provided solely for the convenience of English speaking users.***

<b>First and last name, age and professional address</b>	<b>Duration of Term</b>	<b>Position</b>	<b>Other Positions and Appointments held in any other company over the last five years</b>
<b>Mr. Gilles Brisson</b> French age 63  Innate Pharma 117, Avenue de Luminy 13009 Marseille	First Appointment: General Meeting of shareholders dated June 26, 2007 Renewed by the General Meetings of shareholders dated June 23, 2009 June 29, 2011 and June 28, 2013 Term expires: General Meeting of shareholders of 2015 to be held to vote on the accounts for the fiscal year ending on Dec. 31, 2014	Chairman of the Supervisory Board	Chairman of Mutabilis holding SAS; Chairman of the supervisory board of Ethypharm SA; Member of the Supervisory Board of the Group Carso, Chairman of the Board of Directors of Mauna Kea Technologies (listed company),
<b>Mr. Patrick Langlois<sup>(1)</sup></b> , French age 69  PJJ Conseils 6, Avenue Frederic Le Play 75007 Paris	First Appointment: General Meeting of shareholders dated May 25, 2010 Renewed by the General Meetings of shareholders dated June 29, 2011 and June 28, 2013  Term expires: General Meeting of shareholders of 2015 to be held to vote on the accounts for the fiscal year ending on Dec. 31, 2014	Member of the Supervisory Board	<u>Positions in listed companies:</u> Diaxonhit: Director (2012-2014); Stallergènes (FR): President of the Board of Directors; BioAlliance Pharma (FR) known as Onxeo SA in 214: Chairman of the Board of Directors and of the compensation and nominations committee; <u>Positions in unlisted companies:</u> Scynexis (US): Director and member of the audit committee; Newron (Italy): Director, member of the compensation committee and chairman of the audit committee; Shire (UK): Director, member of the audit committee and the compensation committee (not renewed in 2011); Nanobiotix (France): Chairman of the Board of Directors (not renewed in 2011)
<b>Mr. Philippe Pouletty</b> French age 56 Truffle Capital 5, rue de la Baume 75008 Paris	First Appointment: General Meeting of shareholders dated December 22, 2001. Renewed by the General Meetings of shareholders dated June 26, 2007, June 23, 2009, June 29, 2011 and June 28, 2013.  Term expires: General Meeting of shareholders of 2015 to be held to vote on the accounts for the fiscal year ending on Dec. 31, 2014	Member of the Supervisory Board	Chairman of the Board of Directors of Abivax S.A., Chairman of the Board of Directors of Deinove (listed company), Non Executive Chairman of BMD SA (up to May 29, 2012), Director of the Association of the Marie Lannelongue Surgical Centre, Director representing Truffle Capital SAS on the boards of Vexim SA, Theraclion SA, Plasmaprime SAS, Carmat SA, Pharnext SAS, Biokinesis SAS, Carbios SA, Theradiag, Immune Targeting Systems Ltd( United Kingdom), Symetis (Switzerland), Myopowers (Switzerland); Diaccurate (France), Kephalios (France) and Deinobiotics (France); ; Member of the board of directors and managing director of Truffle Capital SAS, General Manager of Nakostech SARL, Honorary President and Director of France Biotech (Association), positions not renewed at Neovacs SA (2014); Splicos SAS (2013)Wittycell SAS (en 2013);, Cytomics and ITS
<b>Ms. Irina Staatz-Granzer</b> German age 54	First Appointment: General Meeting of shareholders dated June 23, 2009 . Renewed by the General Meetings of shareholders dated June 29, 2011 and	Member and Vice Chairman of the Supervisory	Sta; atz Business Development & Strategy, founder ;Blink Therapeutics Ltd: Chairman (2014); Blink Biomedicals SAS: Chairman

***This is a free translation into English of the executive board report issued in French and provided solely for the convenience of English speaking users.***

Zielstattstrasse 44, D-81379, Munich, Germany	June 28, 2013 Term expires: General Meeting of shareholders of 2015 to be held to vote on the accounts for the fiscal year ending on Dec. 31, 2014	Board	(2015);PLCD (German Pharma Licensing Club), Vice President U3 Pharma AG, CEO
<b>Novo Nordisk A/S<sup>(1)</sup></b> , represented by Mr. Karsten Munk Knudsen <sup>(2)</sup> Danish age 43	First Appointment: General Meeting of shareholders dated June 26, 2007 Renewed by the General Meetings of shareholders dated June 23, 2009, June 29, 2011 and June 28, 2013	Member of the Supervisory Board	Other positions held by Mr Knudsen: None
Novo Allé 2880 Bagsværd Denmark	Term expires: General Meeting of shareholders of 2015 to be held to vote on the accounts for the fiscal year ending on Dec. 31, 2014		
<b>Michael A. Caligiuri</b> American Age 59, OSU James Cancer Hospital, 300W. 10th Avenue, Suite 519, Columbus, OH43210	First Appointment: General Meeting of shareholders dated June 28, 2013 Term expires: General Meeting of shareholders of 2015 to be held to vote on the accounts for the fiscal year ending on Dec. 31, 2014	Member of the Supervisory Board	Member of the Board of Directors of the American Association of Cancer Research (AACR); Member of the Executive Committee of the American Society of Hematology; Member of the Management Committee of Pelotonia; President of the Society for Natural Immunity